Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Gevokizumab"'
Publikováno v:
Pharmaceutics, Vol 16, Iss 9, p 1129 (2024)
The aim of the present study was to develop and evaluate the performance of a methodology to estimate the population pharmacokinetic (PK) parameters along with the inter-individual variabilities (IIVs) from patients’ reported aggregate concentratio
Externí odkaz:
https://doaj.org/article/221be78ee30247ef98cc3af306819570
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundThe cytokine interleukin (IL)-1 plays a pivotal role in immune-mediated disorders, particularly in autoinflammatory diseases. Targeting this cytokine proved to be efficacious in treating numerous IL-1-mediated pathologies. Currently, three
Externí odkaz:
https://doaj.org/article/5598cba60f3c4dc3805be2568e4f732a
Publikováno v:
Current Reviews in Clinical and Experimental Pharmacology. 16:219-227
Background: Interleukin-1 (IL-1) is a pro-inflammatory cytokine that is produced by endothelial cells, smooth muscle cells, and macrophages. It is an important regulator of a complex humoral and cellular inflammatory response. IL-1β is known to be i
Autor:
Giuseppe Lopalco, Gerardo Di Scala, Carlo Salvarani, Claudia Fiorillo, Elena Silvestri, Amedeo Amedei, Alessandra Bettiol, Luca Cantarini, Giacomo Emmi, Alessandra Soriano, Matteo Becatti
Publikováno v:
Rheumatology International. 39:971-990
Behçet's syndrome (BS) is a chronic (auto)-inflammatory disorder characterized by different clusters of symptoms, including mucocutaneous and ocular involvements. Interleukin-1 inhibitors anakinra (ANA), canakinumab (CAN), and gevokizumab (GEV) repr
Autor:
Hana Malcova, Zuzana Strizova, Tomas Milota, Ilja Striz, Anna Sediva, Dita Cebecauerova, Rudolf Horvath
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Frontiers in Immunology
Frontiers in Immunology
Autoinflammatory diseases (AIDs) represent a rare and heterogeneous group of disorders characterized by recurrent episodes of inflammation and a broad range of clinical manifestations. The most common symptoms involve recurrent fevers, musculoskeleta
Autor:
Charles A. Dinarello
Publikováno v:
Curr Otorhinolaryngol Rep
To provide evidence that therapeutic blockade of IL-1 can provide benefit for patients with hearing loss. In this review, we assess clinical trials of the IL-1 receptor antagonist (anakinra), the soluble IL-1 receptor (rilonacept), antibodies to inte
Autor:
Hana Malcova, Tomas Milota, Zuzana Strizova, Dita Cebecauerova, Ilja Striz, Anna Sediva, Rudolf Horvath
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 11 (2021)
Frontiers in Pharmacology, Vol 11 (2021)
Polygenic autoinflammatory diseases (AIDs), such as systemic juvenile idiopathic arthritis (sJIA), adult-onset Still's disease, Kawasaki disease, idiopathic recurrent pericarditis (IRP), Behçet’s Syndrome, Crystal-induced arthropatihes such as gou
Autor:
I. Striz
Publikováno v:
Clinical Science. 131:2241-2256
Interleukin 1 (IL-1) family is a group of cytokines with multiple local and systemic effects, which regulates both innate and adaptive immune responses. Generally, most IL-1 family cytokines express prevailing pro-inflammatory activities (IL-1α, IL-
Publikováno v:
The British journal of ophthalmology. 104(8)
BackgroundBiologics are increasingly used in management of Behçet’s Disease (BD) including ocular BD, but the evidence base is limited, mostly from studies of uveitis and BD manifestations.ObjectiveTo review the evidence base for biologics in the